2024-02-05T07:02:04-06:00 2023-05-31 450250958 Eide Bailly LLP 800 Nicollet Mall Ste 1300 Minneapolis MN 554027033 990 2022-06-01 810503295 Montana Cancer Consortium MONT 4069696060 2132 Broadwater Avenue A1 Billings MT 59102 John Schallenkamp MD President 4069696060 2024-02-01 1 John Schallenkamp MD 999009999 1 Kim Hunwardsen P00484560 6122536500 2024-01-29 2 AAL1 IAL1 2022 2023-04-26 12:10:37Z John Schallenkamp MD 2132 Broadwater Avenue A1 Billings MT 59102 606614 0 X www.mtcancer.org X 1995 MT Promote and supervise cancer research. 7 6 7 8 0 0 897407 606614 0 0 0 0 0 0 897407 606614 0 0 0 0 401696 336664 0 0 0 457515 521126 859211 857790 38196 -251176 606905 361432 -772 4931 607677 356501 The Montana Cancer Consortium (MCC) is an independent nonprofit organization whose mission is to bring state-of-the-art cancer treatment to Montana, Idaho, and Wyoming through National Cancer Institute (NCI) sponsored clinical research. 0 0 729727 Montana Cancer Consortium participates in clinical studies of cancer patients, provides selected candidates with experimental drugs and keeps extensive data on the results of treatment. In the year ending May 31, 2023, Montana Cancer Consortium participated in approximately 120 clinical trials and 203 patients were registered to clinical trials. The Montana Cancer Consortium membership consists of approximately 54 physician members located across 10 affiliate sites in Montana, Northern Wyoming and Idaho. 729727 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 3 0 1 7 1 0 0 0 0 0 0 0 0 0 0 0 0 X 7 6 1 0 0 0 1 1 0 1 0 0 0 1 1 1 1 0 0 0 0 0 X Amanda Dinsdale 4069696063 2132 Broadwater Avenue A1 Billings MT 59102 John Schallenkamp MD President 4.00 X X 0 0 0 Jeffrey Allen MD Vice-President 1.00 X X 0 0 0 Justin Bottsford-Miller MD Vice-President (thru May 5, 2023) 1.00 X X 0 0 0 Benjamin Marchello MD Director (thru Dec 2022) 1.00 X 0 0 0 Michelle Proper MD Director 1.00 X 0 0 0 Christopher Goulet MD Director 1.00 X 0 0 0 James Hueftle MD Director 1.00 X 0 0 0 Justin Thomas MD Director 1.00 X 0 0 0 Amanda Dinsdale Secretary/Treasurer 40.00 X X 85011 0 24766 85011 0 24766 0 0 0 0 Avitus Group PO Box 2506 Billings MT 59102 Benefits & Payroll Management 340792 1 453262 153352 606614 606614 0 0 0 X 122122 61061 61061 152345 152345 2738 2738 38181 38181 21278 17167 4111 21082 21082 325814 325814 624 624 14532 13807 725 17504 17504 29309 29309 25933 25933 22956 22956 Supplemental Protocol F 63199 63199 173 173 857790 729727 128063 0 606905 361432 9878 9878 0 0 606905 361432 -772 4931 -772 4931 X 607677 356501 607677 356501 606905 361432 -251176 0 X 0 0 0 X 962008 1023410 1142804 897407 606614 4632243 962008 1023410 1142804 897407 606614 4632243 69986 4562257 4632243 0.98490 0.97770 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 6368 6368 0 3510 3510 0 0 Form 990, Part VI, Section A, line 1a The Executive Committee consists of not fewer than 3 or more than 5 oncological professional members of the Board of Directors and always includes the President of the Board of Directors. Form 990, Part VI, Section A, line 2 Dr. Schallenkamp and Dr. Goulet have a business relationship. Form 990, Part VI, Section A, line 6 The organization's members consist of all participating principals in the Montana Cancer Consortium NCORP effort. Form 990, Part VI, Section A, line 7a Each active member shall be entitled to one vote for each director to be elected. Form 990, Part VI, Section A, line 8b The Organization has an Executive Committee with authority to act on behalf of the governing body, however the Executive Committee did not meet during the fiscal year. Form 990, Part VI, Section B, line 11b The administrator reviews the 990 return and the board members are provided a copy before filing the form 990. Form 990, Part VI, Section B, line 12c Investigators, individuals who have the potential to enroll clients or patients in NIH clinical trials, are covered by the conflict of interest policy. Investigators are required to file an annual financial disclosure form and undergo Financial Conflict of Interest (FCOI) training every four years. The Program Administrator reviews the completed FCOI annual disclosure forms and FCOI training. The Program Administrator notifies the Principal Investigator of the review completion and any potential conflicts. Restrictions on individuals with a conflict can include, but are not limited to the following: Monitoring of sponsored program by an independent reviewer, modifications to the research or program plan, appointment of oversight panel, public disclosure of significant financial interests, and/or limitations on the Investigator's involvement in Montana Cancer Consortium. Form 990, Part VI, Section B, line 15 An annual evaluation is conducted each year by two supervisors. Form 990, Part VI, Section C, line 19 The public may request copies of the organization's governing documents and financial statements by calling, e-mailing, mailing or requesting in person. Form 990, Part IX, line 11g Contract Payments: Program service expenses 316,914. Management and general expenses 0. Fundraising expenses 0. Total expenses 316,914. Consultant: Program service expenses 8,900. Management and general expenses 0. Fundraising expenses 0. Total expenses 8,900. Billings Interhospital Oncology 2132 Broadwater Avenue Suite A1 Billings MT 59102 810401858 Promote and Supervise Cancer Research MT 501(c)(3) Line 4 Montana Cancer Consortium 1 0 0 0 0 0 0 0 0 0 0 0 1 0 1 1 0 0 0 0